Trial · NCT07893093
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
NCT07893093, Phase 1, Recruiting, Ascletis Pharma (China) Co., Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight. Trials, record NCT07893093. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893093
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
- NCT number
- NCT07893093
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 144 participants, estimated
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Conditions
- Chronic Weight Management
- Interventions
- ASC36 Injection A, for subcutaneous use, ASC36 Placebo Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use, ASC36 Placebo Injection B, for subcutaneous use
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | From baseline to the end of treatment (up to 16 weeks or Day 113) | A summary of AEs, SAEs, and other non-serious adverse events following single SC doses of ASC36 injection |
| Primary | Adverse Events | From baseline to the end of treatment (up to 20 weeks or Day 141) | A summary of AEs, SAEs, and other non-serious adverse events following multiple SC doses of ASC36 injection |
| Secondary | Cmax of ASC36 Injection | From baseline to the end of treatment (up to 20 weeks or Day 141) | Evaluate the peak plasma concentration of ASC36 Injection |
| Secondary | Tmax of ASC36 Injection | From baseline to the end of treatment (up to 20 weeks or Day 141) | Evaluate the time to reach peak plasma concentration of ASC36 Injection |
| Secondary | AUC of ASC36 Injection | From baseline to the end of treatment (up to 20 weeks or Day 141) | Evaluate the area under the plasma concentration-time curve of ASC36 Injection |
| Secondary | Half-life of ASC36 Injection | From baseline to the end of treatment (up to 20 weeks or Day 141) | Evaluate the time required for the plasma concentration of ASC36 to decrease by 50% |
| Secondary | Percent Change From Baseline in Body Weight | From baseline to the end of treatment (up to 20 weeks or Day 141) | Percent Change From Baseline in Body Weight |
| Secondary | Percent Change From Baseline in Waist Circumference | From baseline to the end of treatment (up to 20 weeks or Day 141) | Percent Change From Baseline in Waist Circumference |
| Secondary | Percent Change From Baseline in BMI | From baseline to the end of treatment (up to 20 weeks or Day 141) | Percent Change From Baseline in BMI |
| Secondary | Immunogenicity of ASC36 Injections | From baseline to the end of treatment (up to 20 weeks or Day 141) | Incidence and prevalence of treatment-emergent antidrug antibodies against ASC36 after SC doses of ASC36 injection |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893093
GET https://conductscience.org/api/trials/v1/NCT07893093/registered